Companies › Rivus Pharmaceuticals
1 active drug program in 2 registered trials: 2 Phase 2; Gastroenterology, Metabolic and endocrine; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| HU6 | – | Phase 2 | Non-Alcoholic Fatty Liver Disease; MASH - Metabolic Dysfunction-Associated Steatohepatitis | Feb 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05979779 | HU6 | Phase 2 | Non-Alcoholic Fatty Liver Disease | Gastroenterology | Jan 2025 |
| NCT07491458 | HU6 | Phase 2 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | Metabolic and endocrine | Feb 2027 |
No annotated target.
–
Eccogene Visirna Therapeutics HK Rare Thyroid Therapeutics International Eddingpharm (Zhuhai) Ribotek Biopharmaceuticals (Shandong)
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.